132 related articles for article (PubMed ID: 19345471)
1. Editorial comment on: HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.
Colombo R
Eur Urol; 2010 Jan; 57(1):93-4. PubMed ID: 19345471
[No Abstract] [Full Text] [Related]
2. HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.
Kramer MW; Golshani R; Merseburger AS; Knapp J; Garcia A; Hennenlotter J; Duncan RC; Soloway MS; Jorda M; Kuczyk MA; Stenzl A; Lokeshwar VB
Eur Urol; 2010 Jan; 57(1):86-93. PubMed ID: 19345473
[TBL] [Abstract][Full Text] [Related]
3. Editorial comment on: Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
Gofrit ON
Eur Urol; 2009 Nov; 56(5):836. PubMed ID: 18926619
[No Abstract] [Full Text] [Related]
4. In search of the perfect crystal ball for Ta urothelial cancer.
Chin JL
Eur Urol; 2010 Jan; 57(1):21-2; discussion 23-4. PubMed ID: 19748172
[No Abstract] [Full Text] [Related]
5. Elevation of hyaluronidase-1 and soluble intercellular adhesion molecule-1 helps select bladder cancer patients at risk of invasion.
Aboughalia AH
Arch Med Res; 2006 Jan; 37(1):109-16. PubMed ID: 16314195
[TBL] [Abstract][Full Text] [Related]
6. Bladder cancer in 2010: how far have we come?
Jacobs BL; Lee CT; Montie JE
CA Cancer J Clin; 2010; 60(4):244-72. PubMed ID: 20566675
[TBL] [Abstract][Full Text] [Related]
7. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
9. Editorial comment.
Herr HW
Urology; 2010 Feb; 75(2):391-2; author reply 392. PubMed ID: 20152490
[No Abstract] [Full Text] [Related]
10. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer.
Maffezzini M; Campodonico F; Capponi G; Canepa G; Casazza S; Bandelloni R; Tamagno S; Puntoni M
Anticancer Res; 2010 Nov; 30(11):4761-5. PubMed ID: 21115937
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment on: detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience.
Dalbagni G
Eur Urol; 2010 May; 57(5):849. PubMed ID: 19524355
[No Abstract] [Full Text] [Related]
12. Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer.
Bruins HM; Stein JP
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1091-101. PubMed ID: 18588454
[TBL] [Abstract][Full Text] [Related]
13. Editorial comment.
Damodaran C
J Urol; 2009 Oct; 182(4):1356. PubMed ID: 19683288
[No Abstract] [Full Text] [Related]
14. Editorial comment.
Merseburger AS
J Urol; 2009 Oct; 182(4):1356. PubMed ID: 19683268
[No Abstract] [Full Text] [Related]
15. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of p53, Ki-67, microstaging and microvessel density in pT1G3 bladder tumors: creation of risk groups for progression.
Queipo-Zaragoza JA; Ruiz-Cerda JL; Vera-Donoso CD; Vera-Sempere F; Budia-Alba A; Jimenez-Cruz JF
Scand J Urol Nephrol; 2007; 41(4):283-9. PubMed ID: 17763218
[TBL] [Abstract][Full Text] [Related]
17. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
de Reijke TM
Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
[No Abstract] [Full Text] [Related]
18. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
19. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer.
Nakai Y; Nonomura N; Kawashima A; Mukai M; Nagahara A; Nakayama M; Takayama H; Nishimura K; Okuyama A
Jpn J Clin Oncol; 2010 Mar; 40(3):252-7. PubMed ID: 19995789
[TBL] [Abstract][Full Text] [Related]
20. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
